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Article
The Role of Predictive Biomarkers in Endocervical
Adenocarcinoma: Recommendations From the International
Society of Gynecological Pathologists
Tjalling Bosse, M.D., Ph.D., Sigurd Lax, M.D., Ph.D., Nadeem Abu-Rustum, M.D., Ph.D.,
and Xavier Matias-Guiu, M.D., Ph.D.
Summary: To review the scientific evidence related to predictive biomarkers in cervical
adenocarcinoma (ADC). The authors reviewed the literature regarding predictive biomarkers
in cervical ADC. There were several limitations: (1) there is an overlap between predictive and
prognostic biomarkers, as the vast majority of patients are treated with anticancer strategies;
(2) in many studies and clinical trials, cervical ADC patients are included in a large series of
patients predominantly composed of cervical squamous cell carcinomas; and (3) in most of the
studies, and clinical trials, there is no distinction between human papillomavirus (HPV)-
associated and HPV-independent cervical ADCs, or between various histologic subtypes.
Results obtained from a small group of studies confirm that cervical ADCs exhibit distinct
molecular features as compared with squamous carcinomas, and that there are different
molecular features between different types of cervical ADCs. Promising areas of interest
include ERBB2 (HER2) mutations and PD-L1 expression as predictive biomarkers for anti-
HER2 treatment and immunotherapy, respectively. To date, no definitive data can be
obtained from the literature regarding predictive biomarkers for cervical ADC. Clinical trials
specifically designed for endocervical ADC patients are required to elucidate the predictive
value of HER2 mutations and PD-L1 expression. The distinction between HPV-associated
and HPV-independent cervical ADCs as well as early involvement of pathologists in the design
of future clinical trials are needed to identify new predictive biomarkers in cervical ADC.
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Cervical cancer ranks fourth in incidence and
mortality in women (1). The incidence is particularly
high in developing countries. Ninety-five percent of
cases are caused by persistent human papillomavirus
(HPV) infection (2). Most cervical cancers are squ-
amous cell carcinomas (SCC) but cervical adenocarci-
noma (ADC) has been increasing in both true and
relative incidence (3,4) and in developing nations and
institutions where cervical screening is well established
may be seen in 25% of published series (5).
The updated WHO 2020 classification system recog-
nizes the importance of distinguishing between HPV
positive and negative tumors (designated as HPV
associated and HPV independent, respectively), and
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subdivided the various histologic types under these 2
major groups of cervical ADC (6,7).
In this article, the authors reviewed the literature
regarding prognostic and predictive factors in cervical
ADC. Conventional prognostic factors (such as Silva
patterns of invasion) are mentioned in other manu-
scripts. The authors identified several limitations:
(1) There was an important overlap between predictive
and prognostic biomarkers, as the vast majority of
patients that were included in the studies had been
treated with standard of care therapies, including
chemoradiation therapy.
(2) In many studies and clinical trials, cervical ADC
patients were included in a large series of cases
predominantly composed of SCC patients.
(3) In most of the studies, and clinical trials, there was
no distinction between HPV-associated and HPV-
independent tumors. Moreover, the vast majority
of the studies did not distinguish between histo-
logic subtypes of cervical ADC.
A prognostic biomarker provides information about
the patients’ overall cancer outcome, regardless of the
therapy, whereas a predictive biomarker gives information
about the response to a specific therapeutic intervention.
In addition, a predictive biomarker (such as ER and
HER2/neu in breast cancer) can be a potential target for
therapy (8).
ISGYP established a multidisciplinary panel of mem-
bers (one practicing clinician and 3 pathologists) that
provide care to endocervical carcinoma patients to act as
expert reviewers for the recommendations developed. A
systematic literature review of relevant studies published
between January 2014 and February 2020 was carried out
using the MEDLINE database for combinations of the
keywords related to the topic (endocervical cancer,
adenocarcinoma, molecular, genetics, predictive, tar-
geted therapy, immunotherapy, prognosis, HPV). The
literature search was limited to publications in English.
Priority was given to high-quality systematic reviews,
meta-analyses, and randomized controlled trials, but
studies of lower levels of evidence were also evaluated.
The reference list of each identified article was reviewed
for other potentially relevant articles. An initial docu-
ment was written, and approved by the team members,
and presented in power-point format during a satellite
session in the USCAP meeting in Los Angeles in
March 2020. With all suggestions taken into account, a
manuscript was written and approved by all authors,
and recommendations were submitted for the ISGYP
membership for final approval.
MOLECULAR FEATURES OF CERVICAL ADC
Several studies have addressed the integrated
genomic and molecular characterization of cervical
cancer including a small subset of ADC patients (8,9).
A whole exome sequencing analysis of 115 cervical
carcinomas with normal paired samples included 24
ADC cases and demonstrated ELF3 and CBFB
somatic mutations in 13% and 8% of cases, respec-
tively (9). Moreover, the study confirmed PIK3CA
(16%) and KRAS (8%) mutations, and showed that
the PIK3CA/PTEN pathway was significantly mu-
tated in the ADC group, which is relevant as this
pathway is related to resistance for anti-HER2
therapies (10). TCGA performed an extensive molec-
ular characterization, and included 32 ADC cases,
some of them HPV negative (11). The study
confirmed frequent PIK3CA and KRAS mutations,
and ERBB3 (HER3) mutations. Frequent BCAR4
amplification, putatively associated with anti-HER2
therapy was also detected, and frequent CD274
amplification, putative targets for immunotherapy
(11). A high-throughput genotyping platform, includ-
ing 1250 known mutations in 139 cancer genes was
used in 80 cervical tumors, including 40 SCC and 40
ADC cases (12), a vast majority of them associated
with HPV. In this study, PIK3CA mutation rates did
not differ significantly between ADC and SCC,
whereas KRAS mutations were identified only in
ADC (12). In a recent study in 154 cervical cancers,
including 43 ADC, KRAS mutations were almost
restricted to ADC patients, whereas PIK3CA muta-
tions were more frequent in SCC. TP53 mutations
were more predominant in HPV-independent tumors,
and STK11 genomic alterations showed an associa-
tion with lower overall survival (13).
A transcriptomic signature with molecular networks
associated with SCC and ADC was characterized using
oligomicroarray and pathway analysis (14). Some genes
(KRT17, IGFBP2, CALCA, VIPR1) were differentially
expressed in ADC and SCC. cDNAmicroarray analysis
demonstrated differentially expressed genes specific for
ADC (CEACAM5, TACSTD1, S100P, and MSLN)
(15). In a different study (16), the authors assessed
differential expression between ADC and SCC in a set
of genes including those coding for 12-lipoxygenase
(12-LOX), keratin 4, trypsinogen 2 (TRY2), Rh
glycoprotein C (RhGC), collagen type V alpha 2,
integrin alpha 5, integrin alpha 6, and C-MYC.
The clinicopathologic and prognostic relevance of
KRAS mutation was assessed in a series of 876 invasive
cervical carcinomas, which included 210 ADC cases (17).
KRASmutations were associated with HPV18, and more
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frequently detected in nonsquamous carcinoma, with a
frequency of 7.3% in ADC. The presence of KRAS
mutations was an independent predictor for tumor
recurrence. Another study on cervical cancers, including
55 ADC, analyzed by mass spectrometry by assessing 171
somatic hot-spot mutations, identified KRAS mutations
in 24% of ADC in comparison with 3% of SCC cases
(18). In multivariate analysis, however, mutation status
was not an independent predictor of survival.
Cervical ADC occasionally shows HER2 over-
expression. In one study (19), 46% of ADC showed
positive expression for EGFR and HER2, which
significantly correlated with lymph node metastasis,
stage, and short relapse-free survival. HER2 expres-
sion significantly correlated with tumor size. In a
different study (20), HER2 expression was assessed in
13 cases of gastric-type ADC. Immunostaining was
equivocal in six cases and ERBB2 (HER2) amplifi-
cation was identified in one case. Relevance of HER2
mutations will be discussed latter on.
A few studies have characterized HPV-independent
ADC, including the gastric type (7). Banister et al. (21)
analyzed a series of 212 SCC and 44 ADC, to characterize
HPV-independent cervical cancers. HPV-associated tu-
mors expressed E2F target genes and increased AKT/
MTOR signaling while HPV-independent tumors had
increased WNT/β-catenin and Sonic Hedgehog signaling.
HPV-independent tumors showed a global decrease in
DNA methylation, although there was some promoter-
associated CpGs hypermethylation. HPV-independent
tumors were enriched for nonsynonymous somatic
mutations in TP53, ARID, as well as WNT, and PI3K
pathways. Garg et al. (22) used next-generation sequenc-
ing for 161 unique cancer-driver genes for single-
nucleotide and copy-number variations, gene fusions,
and insertions/deletions in 14 cases. TP53 was the most
frequently mutated gene followed by MSH6, CDKN2A/
B, POLE, SLX4,ARID1A, STK11, BRCA2, andMSH2.
Abnormal p53 expression was observed in 9 cases by
immunohistochemistry, whereas MDM2 gene amplifica-
tion in 12q15 locus was seen in 2 cases that express normal
p53 levels by immunohistochemistry. Hodgson et al. (23)
performed a targeted massively parallel sequencing assay
of 447 cancer genes and 191 regions across 60 genes for
rearrangement detection in 56 ADC samples that included
45 HPV-associated and 11 gastric-type tumors. KRAS,
TP53, and PIK3CA were the most commonly mutated
genes, whereas alterations in TP53, STK11, CDKN2A,
ATM, and NTRK3 were significantly more common in
gastric-type ADC. Tumors associated with adverse out-
come, regardless of the histologic type, more commonly
had alterations in KRAS, GNAS, and CDKN2A. The
association between cervical ADC and STK11 had been
previously noted (24), based on the relationship between
minimal deviation gastric-type ADC and Peutz-Jeghers
syndrome.
As mentioned in previous publications, the pattern
of ADC invasion, according Silva criteria has
prognostic relevance. The Silva classification, how-
ever, is limited to HPV-associated cervical ADC. The
molecular profile of cervical ADC has been associated
with the Silva pattern of invasion, by using targeted
sequencing with the Ion AmpliSeq Cancer Hotspot
Panel v2 that assesses hotspot regions of 50 oncogenes
and tumor suppressor genes (25). Mutations were
frequently found in PIK3CA (30%), KRAS (30%),
MET (15%), and RB1 (10%). PIK3CA, KRAS, and
RB1 mutations were seen exclusively in pattern B or C
subgroups, whereas KRAS mutations correlated with
advanced stage at presentation.
Additional studies have shown molecular abnormal-
ities in cervical ADC at different levels in genes such as
ZNF58S, SOX1, SOX17, EZH2, and L1CAM (26–30).
PREDICTIVE BIOMARKERS OF
CHEMORADIOTHERAPY RESPONSE
A vast majority of patients with advanced cervical
ADC are treated by combined radiation and chemo-
therapy. The mechanisms of resistance to these
anticancer treatments are complex. There is a large
amount of literature suggesting putative markers
involved in response to treatment. It is not the
intention of this section to provide a comprehensive
review on this topic. The vast majority of the
publications refers to cervical cancer in general,
without emphasis on cervical ADC, which is impor-
tant, as there are some studies suggesting poor
response to radiation therapy in ADC, in comparison
with SCC (31–33).
In one review of 19 publications on the mechanisms
involved in resistance to radiation therapy (34), the
authors identified a total of 23 biomarkers, which could
be related to 6 biologic functions, such as apoptosis, cell
adhesion, DNA repair, hypoxia, metabolism, pluripo-
tency, and proliferation. In a different review of
published studies (35), the authors identified 6 immu-
nohistochemical markers with controversial correlation
with chemoradiotherapy response (p53, p21, Ki67,
EGFR, HER2, BCL-2), and 11 immunohistochemical
biomarkers with positive correlation with chemoradio-
therapy (HPV, pAKT, COX-2, nitric oxide synthase,
HIF-1-alpha, HIF-2-alpha, VEGF, NF-kb, Ku80,
EMMPRIN). Moreover, microarray studies have also
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suggested that the expression of sets of genes were
associated with and without recurrence after radiation
therapy (36–39).
Several processes and proteins have been related to
cisplatin resistance in cervical cancer (40), including:
(1) a reduction in the intracellular accumulation of
platinum compounds (CTR1, multidrug resistance
proteins, GSH), (2) increase in DNA damage repair,
(3) inactivation of apoptosis (caspases, BCL family,
NF-kb, p53 signaling), (4) activation of epithelial to
mesenchymal transition, (5) and other mechanisms
such as alteration in DNA methylation, microRNA
profile, stemness, and stress response. D44v6, XRCC,
and mTOR were also related to the prediction of
sensitivity to platinum-type agents in neoadjuvant
chemotherapy (40).
Some other biomarkers have been related to
sensitivity to specific agents, such as CHFR in the
prediction of sensitivity to paclitaxel, WRN in
relation to sensitivity to CPT-11, and HIF-1α in the
prediction of sensitivity to topotecan (40). Neo-
adjuvant treatment would provide a novel window
of opportunity to study response and biomarker
relationships. It would be helpful if pathologists
develop a standardized approach to assess response
to neoadjuvant treatments.
TARGETED THERAPY
Different strategies have been proposed in the treat-
ment of cervical cancer. Yet again, most studies and
clinical trials do not consider ADC patients separately,
so the information must be taken with caution.
Angiogenesis is a critical process in carcinogenesis
and tumor progression. HPV oncoproteins play key
roles in upregulating angiogenesis, through their
effects on p53 degradation and inactivation of pRb,
which lead to increased VEGF pathway and HIF-
1-alpha expression (41). Angiogenesis has been
successfully targeted in cervical cancer, as the results
of the GOG 240 trials (including 310 patients with
SCC and 86 with ADC) and subsequent trials were
published (42–44). Since then, bevacizumab was
approved by the FDA and became standard of care
in a subset of patients with advanced cervical cancer.
No predictive biomarker of antiangiogenic response
has reached clinical practice.
Several other drugs and corresponding predictive
biomarkers have been proposed (45,46). They include
EGFR inhibitors (47–49) and PARP-1 inhibitors
(50,51), because of the expression of EGFR (18) and
presence of homologous recombination-related gene
mutations (52) in cervical cancer. None of them,
however, have reached clinical practice. Tisotumab
vedotin, an antibody-drug conjugate targeting tissue
factor has got encouraging results (53), but no specific
predictive biomarker has been proposed.
A promising targeted therapy approach at present is
ERBB2 (HER2) and ERBB3 (HER3), the genes that
encode for HER2 and HER3. As mentioned before,
HER2 overexpression and HER2 amplification were
previously shown in cervical ADC. Somatic mutations
in ERBB2/3 (HER2/3) were found in a wide range of
cancers (54), and lead to constitutive HER2/3 activation.
HER2mutations were detected in 4% to5.5% of cervical
cancers (54,55). PIK3CA mutations represented one of
the most frequent co-alterations in HER2-mutant
cancers (56); and this is a problem, as PIK3CA
mutations are known to result in resistance to anti-
HER2 treatment (9). These preliminary studies have
shown that a subset of patients with cervical cancer and
HER2 inhibition achieved complete/partial response
and stable disease in basket trials (54). In one study with
1015 patients with cervical cancer, HER2 mutations
were found in 4.5% ADC, but only in 2.1% SCC (56).
HER2 mutations frequently coexisted with PIK3CA or
KRAS mutations. In that series of cases, 33 non-
synonymous somatic HER2 mutations were detected,
including 30 missense mutations and 3 in-frame
deletions. Nineteen HER2 mutations were located
within the extracellular domain, four in the trans-
membrane domain, and 10 in the Kinase domain. The
most prevalent mutation spot was S310F (6 cases),
followed by A270S (5 cases). Among patients who were
tested for both HER2 gene mutations and overexpres-
sion/amplification, no concurrence of mutation and
overexpression/amplification was found. A case report
has shown successful result of HER2 inhibition in 1
patient with advanced cervical ADC with HER2
amplification (57). It appears that HER2 inhibition
can be an interesting tool for ADC patients with HER2
mutation or amplification, and maybe with BCAR4
amplification. A combined therapy targeting simulta-
neously HER2 and PIK3CA has also been suggested
(58). Pathologists have experience in the quality control
of HER2 expression assessment (59,60). Interpretation
of predictive biomarkers, such as HER2, has shown to
be context specific, as seen in differences in criteria for
breast and gastric carcinoma (61). Therefore, it is worth
mentioning that there is still insufficient experience on
how to score HER2 immunohistochemistry in the
context of cervical ADC. Gynecologic pathology studies
focusing on scoring and quantitating HER2 expression
in cervical ADC should be encouraged.
S105BIOMARKERS IN ENDOCERVICAL ADENOCARCINOMA
Int J Gynecol Pathol Vol. 40, No. 2 Supplement 1, March 2021
IMMUNOTHERAPY
The main objective of cancer immunotherapy is to
enhance tumor antigen-specific immune responses
that can target tumor cells. Many different studies
have demonstrated that immunotherapy may be
helpful in the treatment of a variety of tumors. The
emergence of immune checkpoint inhibitors has
opened a new door to cancer therapy.
Cervical cancer is a good candidate tumor for
immunotherapy approaches. There are several rea-
sons for this. Cervical cancer has a relatively high rate
of tumor mutational burden (62), frequent amplifica-
tion of immune targets (11), and frequent involvement
of HPV. There is increasing evidence showing that
immune checkpoint inhibitors may have a potential
role in the treatment of virus-related cancers (63). It
has been shown that HPV E7 may increase PD-L1
expression after transfection into cancer cells (64).
Immune checkpoints such as programmed death 1
(PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-
4) are membrane-bound molecules, which are
expressed on immune cells. Immune checkpoint
inhibitors block the binding of immune checkpoint
molecules to their ligands, reversing the inactivation
of T cells, enhancing the immune response of T cells.
These inhibitors may have a role in virus clearance
and may have a greater effect in virus-associated
cancers (63).
In a recent overview about the role of biomarkers
for the prediction of response to checkpoint immu-
notherapy (65), it is shown that cervical cancer is
frequently positive for PD-L1, and show a moderate
mutational burden, with 5-6 mutations per megabase.
Higher ratios of CD8+ tumor-infiltrating lymphocytes
to CD4+ T regulatory cells have been associated with
improved survival. Response rate of cervical cancer to
checkpoint immunotherapy is within the range of 10%
to 25%.
PD-L1 expression was assessed in 2 cohorts of primary
cervical carcinomas (156 SCC and 49 ADC), and
matched primary and metastatic tumors (96 SCC
and 31 ADC) (66) using the E1L3N clone on an
automated Ventana immunostainer. Tumor cells were
designated positive when >5% of tumor cells were
positive. Distinction was made between diffuse (through-
out the tumor), or marginal (interphase between tumor
and stroma). Scores were also calculated for PD-
L1-positive tumor-infiltrating immune cells. SCC was
more frequently positive for PD-L1 and contained more
PD-L1-positive tumor-associated macrophages. Disease-
specific survival was significantly worse in ADC patients
with PD-L1-positive tumor-associated macrophages
compared with ADCA patients without PD-L1-positive
tumor-associated macrophages. No difference between
primary and metastatic tumors was seen. In another study
(67), PD-L1 (clone SP142), by combining intensity and
percentage of positive cells, was expressed in 32 of 93
(34.4%) cervical carcinomas, including 2 of 12 (16.7%)
ADC.
A meta-analysis including seven studies with 783
patients (68) also suggested that PD-L1 overexpres-
sion was associated with poor overall survival. The
methodology was different, and the number of ADC
cases was variable (69–71). One study including 127
samples was limited to ADC (72). The density of
immune cells and expression levels were compared
between the tumor cell groups and stroma, using
digital image analysis. Expression of PD-L1 on tumor
cells was found in 17.3% of the cases. A higher density
of stroma-infiltrating lymphocytes and macrophages
was found in PD-L1-positive tumors than in negative
tumors. In this study, patients with PD-L1-positive
tumors tended to experience longer survival. In one
study with 97 patients, 7 of them ADC (73), PD-L1
expression correlated with tumor-infiltrating lympho-
cytes, and response to neoadjuvant chemotherapy.
Four phase 1 and 2 clinical trials assessed the value
of check point inhibitors in cervical cancers. In 3 of
them, ADC patients were included. In one of them
(74), Ipilimumab was administered to 42 previously
treated patients with cervical cancer, 13 of them with
ADC. PD-L1 expression, as assessed by E1L3N
clone, was negative in 20 patients, positive (10%) in
4, and positive (> 10%) in additional 4 patients. There
was partial response in 1 patient and stable disease in
10. PD-L1 expression was not predictive of therapeu-
tic benefit and PD-L1 expression did not change
during treatment. In the Keynote-028 trial (75),
Pembrolizumab was administered to 22 previously
treated patients with cervical cancer, including a
single patient with ADC. PD-L1 expression, assessed
by the 22C3 clone with a cutoff of > 1% was positive
in tumor cells in 18 cases, and in 6 cases in both tumor
and stromal cells. There was partial response in 4
patients, and stable disease in 3 patients. Finally, in
the Keynote-158 study (76), Pembrolizumab was
administered to 98 patients with previously treated
cervical cancer, including 5 patients with ADC. PD-
L1 was assessed by the 22C3 clone, by using the
combined positive score (CPS) (> 1), which is a ratio
of tumor lymphocytes and macrophages by the total
of tumor cells. All ADC were positive (CPS > 1). The
objective response rate was higher in patients with
PD-L1-positive tumors. No responses were observed
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in patients with PD-L1-negative tumors, but the
number of cases was too small to draw conclusions.
After publication of the Keynote-158 trial, the Food
and Drug Administration (FDA) approved pembro-
lizumab for patients with recurrent or metastatic
cervical cancer with disease progression on or after
chemotherapy, whose tumors express PD-L1 (CPS of
1 or higher), as determined by the FDA-approved
companion test, by 22C3 clone. Until new data is
provided (with additional clinical trials with other
drugs, a significant proportion of ADC patients, and
assessment the different antibodies available as best
companion diagnostic test), it seems reasonable to
give support to the current FDA-approved guidelines.
There are several ongoing phase III randomized trials
(Keynote-826,-NCT03635567, BEATcc-NCT03556839,
GOG3016-NCT03257267) with several immune check-
point inhibitors in women with metastatic and/or
recurrent cervical cancers.
Tumor microenvironment can have an impact on
prognosis. Several studies have shown an improved
survival associated with an increase in the number of
tumor-infiltrating lymphocytes (77,78). There is an
association between a high number of intratumor CD8+
lymphocytes and absence of lymph node metastasis (79).
However, the perspectives of immunotherapy in
cervical carcinoma go beyond checkpoint inhibitors.
TIM3 is a candidate target that is expressed on
immune cells, and contributes to immune tolerance
(80). TIM3 is expressed in cervical tumors, and may
be associated with tumor progression (81). Other
interesting strategies are therapeutic vaccines and
adoptive cell therapies.
Recommendation 1
Expert gynecologic pathologists should take the
lead in developing robust guidelines for testing and
scoring HER2 and PD-L1 immunohistochemistry to
facilitate standardization in clinical trials. It is
strongly recommended to interpret and report pre-
dictive biomarkers to response of treatment in
endocervical ADC in correlation with well-established
pathologic parameters.
Recommendation 2
Until specific recommendations are validated for
endocervical ADC, prediction of immunotherapy
response criteria is identical to that for squamous
cervical cancer. At present, PD-L1 immunohisto-
chemistry (CPS of 1 or higher), as determined by the
FDA-approved companion test, by 22C3 clone, is
recommended for pembrolizumab treatment of pa-
tients with recurrent or metastatic cervical cancer with
disease progression on or after chemotherapy.
Recommendation 3
With the exception of PD-L1, and based on the lack
of scientific evidence at the present time, no other
biomarker is recommended for the prediction of
treatment response in endocervical ADC.
COMBINATION OF TREATMENTS
Radiation therapy is an effective treatment for local
tumor control, but may also elicit a systemic effect,
which can lead to an antitumor effect that can kill
cancer cells outside of the radiation filed. This been
reported as the Abscopal effect (82,83). The mecha-
nisms responsible for the Abscopal effect are not well
understood, and the immune system is thought to play
an important role. It has been suggested that immune
modulation from PD-1/PD-L1 inhibitors and radia-
tion therapy through nonredundant pathways may
contribute to synergistic activity, which is the basis of
combination of radiation therapy and immunother-
apy. Some studies show increased PD-L1 positivity in
tissue samples, after radiation therapy (84).
CLINICAL TRIALS
To date, no definitive data can be obtained from the
literature regarding predictive biomarkers for treat-
ment response in cervical ADC (Table 1). So far,
clinical trials have predominantly included patients
with SCC. Clinical trials specifically designed for
endocervical ADC patients are encouraged to
elucidate the predictive value of HER2 amplification
and mutations as well as PD-L1 expression.
Involvement of pathologists in designing these clinical
trials is needed to identify new predictive biomarkers in
cervical ADC. Although clinical trials are not the main
domain of gynecological pathologists, it is important to
emphasize that their involvement is needed for ideal
methodologic strategy. Pathologists should take the
lead in developing robust guidelines for testing and
scoring HER2 and PD-L1 immunohistochemistry to
facilitate standardization in clinical trials. Given the
relative rarity of ADC, an international multi-
institutional effort is required to move this field
forward, particularly to recruit enough patients with
HPV-independent ADC to achieve the appropriate
statistical power for an HPV-independent arm.
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Recommendation 4
Clinical trials specifically designed for HPV-associated
and HPV-independent endocervical ADC patients are
strongly encouraged to elucidate the predictive value of
some biomarkers (ERBB2 PD-L1, and others). Trials
combining the unbalanced number of patients with ADC
(including HPV-independent disease) and SCC may yield
results not necessarily applicable to endocervical adeno-
carcinoma patients.
Recommendation 5
Involvement of expert gynecologic pathologists in
the design of future clinical trials is strongly recom-
mended to appropriately identify new predictive
biomarkers in cervical adenocarcinoma.
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